Page 1 | Search Results | Blood | American Society of Hematology

1-17 of 17

Sort by

Sort Order Select

Journal Articles

The Contribution of Proteasome Subunits to Myeloma Cell Viability and Proteasome Inhibitor Sensitivity

Chang-Xin Shi, PhD, Yuan Xiao Zhu, PhD, Laura Ann Bruins, BS, Cecilia Bonolo De Campos, PhD, William Stewart, Esteban Braggio, PhD, A Keith Stewart, M.B. Ch.B.

Blood (2019) 134 (Supplement_1): 4337.

https://doi.org/10.1182/blood-2019-127149

Published: 2019

Journal Articles

Lenalidomide, Pomalidomide and CC-220 Resistant Multiple Myeloma: Confirmation of Role of CRBN/IRF4 Axis and Identification of Multiple Disruption Mechanisms

Yuan Xiao Zhu, PhD, Chang-Xin Shi, PhD, Laura Ann Bruins, BS, Xuewei Wang, PhD, Daniel Riggs, PhD, Brooke Porter, Jonathan Ahmann, BS, Esteban Braggio, PhD, P. Leif Bergsagel, MD, A. Keith Stewart, MBChB, MBA

Blood (2017) 130 (Supplement 1): 4369.

https://doi.org/10.1182/blood.V130.Suppl_1.4369.4369

Published: 2017

Journal Articles

PIKfyve Inhibitors for the Treatment of Multiple Myeloma

Cecilia Bonolo De Campos, PhD, Yuan Xiao Zhu, PhD, Chang-Xin Shi, PhD, Laura Ann Bruins, BS, Joachim L Petit, PhD, Alysia N Polito, BS, Meaghen E Sharik, BS, Caleb K Stein, MS, Gregory J Ahmann, BS, Ilsel D Lopez Armenta, BS, Nikolai Sepetov, PhD, Sergei Romanov, PhD, P. Leif Bergsagel, MD, Marta Chesi, PhD, Nathalie Meurice, PhD, A. Keith Stewart, MBChB, MBA

Blood (2017) 130 (Supplement 1): 4423.

https://doi.org/10.1182/blood.V130.Suppl_1.4423.4423

Published: 2017

Journal Articles

Lenalidomide Inhibits Thioredoxin Reductase (TrxR) in Multiple Myeloma (MM) Cells but Direct Inhibition of Trxr and Thioredoxin (Trx) Can Bypass Requirement of Cereblon (CRBN)

Sinto Sebastian Chirackal, PhD, Esteban Braggio, PhD, Yuan Xiao Zhu, PhD, Chang-Xin Shi, PhD, Scott Van Wier, Gregory Ahmann, Veronica Gonzalez-Calle, MD, Marta Chesi, PhD, Leif Bergsagel, MD, Keith Stewart, M.B., Ch.B., Rafael Fonseca, MD

Blood (2016) 128 (22): 4482.

https://doi.org/10.1182/blood.V128.22.4482.4482

Published: 2016

Journal Articles

Immunomodulatory Drugs Inhibit H 2 O 2 Decomposition in Multiple Myeloma Cells and Its Mediated Cytotoxicity Is Determined By Cellular Antioxidative Capacity

Sinto Sebastian Chirackal, PhD, Yuan Xiao Zhu, PhD, Esteban Braggio, PhD, Chang-Xin Shi, PhD, Sonali Panchabhai, MBBS, Gregory Ahmann, BS, Scott A. Van Wier, BS, Marta Chesi, PhD, Leif Bergsagel, MD PhD, Keith Stewart, MD, Rafael Fonseca, MD

Blood (2015) 126 (23): 2475.

https://doi.org/10.1182/blood.V126.23.2475.2475

Published: 2015

Journal Articles

Crispr Sgrnas Genome-Wide Screen Identifies the Proteasome Regulatory Subunit PSMC6 As a Bortezomib Resistance Gene in Human Multiple Myeloma Cells

Chang-Xin Shi, PhD, Klaus M Kortum, MD, Yuan Xiao Zhu, PhD, Patrick Jedlowski, Esteban Braggio, PhD, Laura Ann Bruins, Patrick G. Votruba, M.S., Moulun Luo, PhD, Robert A. Stewart, Jonathan M. Ahmann, A. Keith Stewart

Blood (2015) 126 (23): 450.

https://doi.org/10.1182/blood.V126.23.450.450

Published: 2015

Journal Articles

Targeted Sequencing of Relapsed/Refractory Myeloma Patients Identifies an Enrichment of Mutations in Cereblon and MAPK Pathways

Blood (2015) 126 (23): 723.

https://doi.org/10.1182/blood.V126.23.723.723

Published: 2015

Journal Articles

Identification of FAM46C As a Multiple Myeloma Repressor

Yuan Xiao Zhu, PhD, Chang-Xin Shi, PhD, Patrick Jedlowski, Klaus Martin Kortum, Laura Ann Bruins, Jonathan Ahmann, Esteban Braggio, PhD, Xuewei Wang, A. Keith Stewart

Blood (2015) 126 (23): 836.

https://doi.org/10.1182/blood.V126.23.836.836

Published: 2015

Journal Articles

Ikaros Degradation Efficiency Correlates with Response of Multiple Myeloma (MM) Cells to IMiD Therapy and Is Blocked By Proteasome Inhibitors

Chang-Xin Shi, PhD, Yuan Xiao Zhu, PhD, Patrick Jedlowski, Laura Bruins, Martin Kortuem, MD, A. Keith Stewart, MD

Blood (2014) 124 (21): 2247.

https://doi.org/10.1182/blood.V124.21.2247.2247

Published: 2014

Journal Articles

Genome Wide Studies in Multiple Myeloma Identify XPO1/CRM-1 As a Critical Target Validated Using the Selective Inhibitor of Nuclear Export (SINE) KPT-276

Jessica Schmidt, Esteban Braggio, Ph.D., Marta Chesi, PhD, Jan Egan, PhD, Yuan Xiao Zhu, PhD, Chang-Xin Shi, PhD, Stephen Palmer, Victoria Garbitt, Dilara McCauley, PhD, Sharon Shacham, PhD MBA, Michael Kauffman, MD, PhD, Leif Bergsagel, MD, Keith Stewart, MD

Blood (2012) 120 (21): 573.

https://doi.org/10.1182/blood.V120.21.573.573

Published: 2012

Journal Articles

Cereblon Expression Predicts Response, Progression Free and Overall Survival After Pomalidomide and Dexamethasone Therapy in Multiple Myeloma

Blood (2012) 120 (21): 194.

https://doi.org/10.1182/blood.V120.21.194.194

Published: 2012

Journal Articles

The Myeloma Genome in Drug Refractory Extra-Medullary Disease Identifies Mutations in Proteasome, Cereblon and Glucocorticoid Pathways

Jan Egan, PhD, Klaus Martin Kortuem, MD, Chang-Xin Shi, PhD, Jessica Schmidt, David Craig, PhD, John Carpten, PhD, Keith Stewart, MBA, MB, CHB

Blood (2012) 120 (21): 3968.

https://doi.org/10.1182/blood.V120.21.3968.3968

Published: 2012

Journal Articles

Cereblon Expression Is Required for the Anti-Myeloma Activity of Lenalidomide and Pomalidomide

Yuan Xiao Zhu, PhD, Esteban Braggio, PhD, Chang-Xin Shi, PhD, Jessica Schmidt, Laura Bruins, Steven R. Schuster, MD, Rafael Fonseca, MD, P. Leif Bergsagel, MD, Chad C. Bjorklund, Ph.D., Robert Z. Orlowski, MD, PhD, A. Keith Stewart, MD

Blood (2011) 118 (21): 127.

https://doi.org/10.1182/blood.V118.21.127.127

Published: 2011

Journal Articles

RNAi Screen of the Druggable Genome Identifies Modulators of Proteasome Inhibitor Sensitivity in Myeloma Including CDK5.

Yuan Xiao Zhu, PhD, Rodger E. Tiedemann, MBChB, PhD, FRACP, FRCPA, Chang-Xin Shi, PhD, Jessica Schmidt, BS, Laura Bruins, Jonathan J Keats, PhD, Holly Yin, PhD, Chris Sereduk, Spyro Mousses, PhD, A. Keith Stewart, MBChB

Blood (2009) 114 (22): 602.

https://doi.org/10.1182/blood.V114.22.602.602

Published: 2009

Journal Articles

Kinome and Druggable Genome Vulnerabilities in Multiple Myeloma Identified by Systematic RNA Interference Screening.

Rodger E. Tiedemann, MD, PhD, Yuan-Xiao Zhu, PhD, Holly Yin, PhD, Quick Que, PhD, Chang-Xin Shi, PhD, Spyro Mousses, PhD, Keith Stewart, MD

Blood (2007) 110 (11): 391.

https://doi.org/10.1182/blood.V110.11.391.391

Published: 2007

Journal Articles

PRL3 Is a Mediator of IL6/STAT3 Signaling and Defines a Population of Multiple Myeloma Patients Distinct from Those That Activate NFkB.

Michael Sebag, MD, PhD, Keith Stewart, MD, Chang-Xin Shi, PhD, Yuan-Xiao Zhu, PhD, Wee-Joo Chng, MD, Jonathan Keats, PhD, Rodger E. Tiedemann, MD, PhD, Rafael Fonseca, MD, Marta Chesi, PhD, Peter Leif Bergsagel, MD

Blood (2007) 110 (11): 671.

https://doi.org/10.1182/blood.V110.11.671.671

Published: 2007

Journal Articles

Transgenic Blimp-1 Promoter Directs Hematopoietic Specific Gene Expression in Mice.

Ding-Yan Wang, PhD, Xiao-Yan Wen, PhD, Bo Gao, PhD, Gillian Sleep, BSc, Lihua Zhuang, PhD, Chang-Xin Shi, PhD, Zhihua Li, MD, Yi Zhao, MD, Hui Deng, BSc, Nadine Mbuyi, BSc, Tian-Ru Jin, PhD, Joseph Cheung, BSc, A. Keith Stewart, MD

Blood (2004) 104 (11): 4194.

https://doi.org/10.1182/blood.V104.11.4194.4194

Published: 2004

NARROW

The Contribution of Proteasome Subunits to Myeloma Cell Viability and Proteasome Inhibitor Sensitivity

Lenalidomide, Pomalidomide and CC-220 Resistant Multiple Myeloma: Confirmation of Role of CRBN/IRF4 Axis and Identification of Multiple Disruption Mechanisms

PIKfyve Inhibitors for the Treatment of Multiple Myeloma

Lenalidomide Inhibits Thioredoxin Reductase (TrxR) in Multiple Myeloma (MM) Cells but Direct Inhibition of Trxr and Thioredoxin (Trx) Can Bypass Requirement of Cereblon (CRBN)

Immunomodulatory Drugs Inhibit H 2 O 2 Decomposition in Multiple Myeloma Cells and Its Mediated Cytotoxicity Is Determined By Cellular Antioxidative Capacity

Crispr Sgrnas Genome-Wide Screen Identifies the Proteasome Regulatory Subunit PSMC6 As a Bortezomib Resistance Gene in Human Multiple Myeloma Cells

Targeted Sequencing of Relapsed/Refractory Myeloma Patients Identifies an Enrichment of Mutations in Cereblon and MAPK Pathways

Identification of FAM46C As a Multiple Myeloma Repressor

Ikaros Degradation Efficiency Correlates with Response of Multiple Myeloma (MM) Cells to IMiD Therapy and Is Blocked By Proteasome Inhibitors

Genome Wide Studies in Multiple Myeloma Identify XPO1/CRM-1 As a Critical Target Validated Using the Selective Inhibitor of Nuclear Export (SINE) KPT-276

Cereblon Expression Predicts Response, Progression Free and Overall Survival After Pomalidomide and Dexamethasone Therapy in Multiple Myeloma

The Myeloma Genome in Drug Refractory Extra-Medullary Disease Identifies Mutations in Proteasome, Cereblon and Glucocorticoid Pathways

Cereblon Expression Is Required for the Anti-Myeloma Activity of Lenalidomide and Pomalidomide

RNAi Screen of the Druggable Genome Identifies Modulators of Proteasome Inhibitor Sensitivity in Myeloma Including CDK5.

Kinome and Druggable Genome Vulnerabilities in Multiple Myeloma Identified by Systematic RNA Interference Screening.

PRL3 Is a Mediator of IL6/STAT3 Signaling and Defines a Population of Multiple Myeloma Patients Distinct from Those That Activate NFkB.

Transgenic Blimp-1 Promoter Directs Hematopoietic Specific Gene Expression in Mice.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only